Navigation Links
Genalyte Awarded $500,000 SBIR Grant To Develop Multiplexed Assays For Early Detection And Monitoring Of Type 1 Diabetes
Date:12/11/2012

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Genalyte, Inc. today announced that it has been awarded a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of Type 1 diabetes that will run on Genalyte's innovative MaverickTMDetection System.  The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.  Genalyte's novel multiplexing technology simultaneously screens for the detection of multiple autoantibodies and other proteins using a one-step, 15-minute process. 

The SBIR-funded program initially will create a basic multiplexed assay to detect autoimmune response for known targets for Type 1 diabetes.  It will then expand the approach to profile autoantibody response by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.

"The pioneering work of the late Dr. Eisenbarth and others established that the development of Type 1 diabetes is an incremental process, as rogue elements of the immune system over time compromise and eventually destroy the pancreatic islet cells that produce insulin," noted Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.  "The unique capabilities of our Maverick multiplexed detection platform have the potential to provide researchers and clinicians with the tools to detect and track this process from a very early stage, when therapeutic intervention to interrupt the process could be feasible."

Once the autoantibody panels have been developed and tested, they will be refined and validated using samples from patients with Type 1 diabetes.  Genalyte expects to collaborate on this phase of the project with researchers from Dr. Eisenbarth's laboratory at the Barbara Davis Diabetes Center of the University of Colorado School of Medicine in Denver.

Dr. Gleeson added, "From early on we envisioned that the unprecedented multiplexing capabilities of our Maverick technology would make it possible to change the way that certain diseases are diagnosed and treated.  We are delighted that NIDDK is supporting development of these assays that have the potential to make this goal a reality for the millions of individuals at risk of Type 1 diabetes."

Genalyte's Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.  The Maverick system's one-step approach automates the washes, incubations, reagent processing and other steps needed for the analysis.  Semi-quantitative results are reported for each analyte, eliminating the need for reflex testing.  The Maverick platform has a large dynamic range and excellent sensitivity, with outstanding reproducibility.

The Maverick Detection System and its ENA 4 and ENA 6 Assay Kits are currently commercially available.  They simultaneously screen for several of the most common antibodies found in autoimmune connective tissue disorders, such as lupus (SLE), Sjogren's syndrome, and scleroderma.  The assay results are highly reproducible, show excellent correlation to ELISA and are up to ten times more sensitive.  Assay kits for advanced SLE testing, rheumatoid arthritis and Type I diabetes are available under the Genalyte Technology Access program. 

For more information about the Maverick platform and Genalyte's new Custom Chip Spotting Service, visit www.genalyte.com.  Maverick assays are currently available for research use only.

About Genalyte
Founded in 2007, Genalyte, Inc. is commercializing the MaverickTM detection platform based on the company's revolutionary Microring Sensor TechnologyTM a new approach to multiplexing that leverages advances in silicon photonics to reduce or eliminate sample preparation, provide scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieve excellent sensitivity and up to eight logs of dynamic range.Contacts:Genalyte, Inc.

Media:Martin Gleeson, PhD

BLL Partners, LLCChief Scientific Officer

Barbara Lindheim+1 858 750-4470

+1 212 584-2276martin@genalyte.com

blindheim@bllbiopartners.com


'/>"/>
SOURCE Genalyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Florida Blue Awarded Certified Center of Excellence by BenchmarkPortal for Second Consecutive Year
2. Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
3. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
4. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
7. Breast Cancer Survivor Awarded Top Prize In 2012 Oncology On Canvas(SM) Art Competition
8. New Snoring Therapy Awarded The Prestigious Spark Award
9. Harrisvaccines Awarded Vaccine Product Licensure
10. Healionics Awarded $900k Grant from NIH
11. Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):